Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  S. Kedia,et al.  Management of acute severe ulcerative colitis. , 2014, World journal of gastrointestinal pathophysiology.

[3]  C. Buskens,et al.  Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[4]  J. Rhodes,et al.  Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit , 2013, Alimentary pharmacology & therapeutics.

[5]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[6]  D. Jewell,et al.  Meta‐analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis , 2013, Alimentary pharmacology & therapeutics.

[7]  S. Ng,et al.  A Review of Mortality and Surgery in Ulcerative Colitis: Milestones of the Seriousness of the Disease , 2013, Inflammatory bowel diseases.

[8]  B. Feagan,et al.  Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews , 2013, Inflammatory bowel diseases.

[9]  J. Halfvarson,et al.  Infliximab as rescue therapy in hospitalised patients with steroid‐refractory acute ulcerative colitis: a long‐term follow‐up of 211 Swedish patients , 2013, Alimentary pharmacology & therapeutics.

[10]  W. Sandborn,et al.  52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants , 2013, Inflammatory bowel diseases.

[11]  Edgar Ramiterre,et al.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study , 2013, Annals of the rheumatic diseases.

[12]  Sergio Gutierrez-Ureña,et al.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study , 2013, Annals of the rheumatic diseases.

[13]  L. Guidi,et al.  Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission , 2013, Inflammatory bowel diseases.

[14]  O. Dewit,et al.  Randomised clinical trial: once‐ vs. twice‐daily prolonged‐release mesalazine for active ulcerative colitis , 2013, Alimentary pharmacology & therapeutics.

[15]  G. Radford-Smith,et al.  Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[16]  J. Coffey,et al.  Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis , 2013, International Journal of Colorectal Disease.

[17]  S. Travis,et al.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study , 2013, Gut.

[18]  A. Ford,et al.  Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. , 2013, World journal of gastroenterology.

[19]  H. Lehnert,et al.  Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients , 2013, Alimentary pharmacology & therapeutics.

[20]  A. Cheifetz,et al.  Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis , 2013, The American Journal of Gastroenterology.

[21]  John Penders,et al.  Probiotics in the Management of Inflammatory Bowel Disease , 2012, Drugs.

[22]  P. Austin,et al.  Impact of Clostridium difficile colitis on 5‐year health outcomes in patients with ulcerative colitis , 2012, Alimentary pharmacology & therapeutics.

[23]  R. Bagin,et al.  Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. , 2012, Gastroenterology.

[24]  M. V. van Oijen,et al.  High mucosal healing rates in 5‐ASA‐treated ulcerative colitis patients: Results of a meta‐analysis of clinical trials , 2012, Inflammatory bowel diseases.

[25]  S. Targan,et al.  Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[26]  B. Feagan,et al.  Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.

[27]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[28]  L. Peyrin-Biroulet,et al.  Ulcerative colitis as a progressive disease: the forgotten evidence. , 2012, Inflammatory bowel diseases.

[29]  S. Targan,et al.  Abatacept for Crohn's disease and ulcerative colitis. , 2012, Gastroenterology.

[30]  G. D'Haens,et al.  Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[31]  P. Rutgeerts,et al.  943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial , 2012 .

[32]  P. Rutgeerts,et al.  943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC , 2012 .

[33]  D. Drossman,et al.  Narcotic use for inflammatory bowel disease and risk factors during hospitalization , 2012, Inflammatory bowel diseases.

[34]  T. Matsui,et al.  Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis , 2012, Inflammatory bowel diseases.

[35]  D. Hommes,et al.  Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. , 2012, Journal of Crohn's & colitis.

[36]  W. Bemelman,et al.  The effect of appendectomy on the course of ulcerative colitis: a systematic review , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[37]  A. Krag,et al.  Safety and efficacy of Profermin® to induce remission in ulcerative colitis. , 2012, World journal of gastroenterology.

[38]  U. Navaneethan,et al.  Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. , 2012, Journal of Crohn's & colitis.

[39]  P. Rutgeerts,et al.  Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies , 2012, Inflammatory bowel diseases.

[40]  P. Hellström,et al.  Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid‐Refractory Ulcerative Colitis: A Retrospective Observational Study , 2012, Inflammatory bowel diseases.

[41]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[42]  A. Griffiths,et al.  Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements , 2012, The American Journal of Gastroenterology.

[43]  P. Moayyedi,et al.  Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[44]  W. Sandborn.  Mucosal healing with infliximab: results from the active ulcerative colitis trials. , 2012, Gastroenterology & hepatology.

[45]  L. Leifeld,et al.  Mesalazine granules are superior to Eudragit‐L‐coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis , 2011, Alimentary pharmacology & therapeutics.

[46]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[47]  A. Dixon,et al.  Laparoscopic restorative proctocolectomy: a 10‐year experience of an evolving technique , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[48]  L. Peyrin-Biroulet,et al.  Ulcerative colitis as a sole mucosal disease: another misunderstanding? , 2011, Gut.

[49]  C. O'Morain,et al.  Review article: defining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[50]  O. Coatmeur,et al.  Appendicectomy as a potential therapy for refractory ulcerative proctitis , 2011, Alimentary pharmacology & therapeutics.

[51]  L. Guidi,et al.  Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience , 2011, International Journal of Colorectal Disease.

[52]  J. Gisbert,et al.  Cyclosporin Versus Infliximab in Severe Acute Ulcerative Colitis Refractory to Intravenous Steroids: A Randomized Trial , 2011 .

[53]  P. Rutgeerts,et al.  Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial , 2011 .

[54]  G. D'Haens,et al.  Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis , 2011 .

[55]  S. Saxena,et al.  Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[56]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[57]  P. Moayyedi,et al.  Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[58]  L. Kupčinskas,et al.  3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. , 2011, Journal of Crohn's & colitis.

[59]  W. Sandborn,et al.  52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants , 2011, Gut.

[60]  D. Rubin,et al.  Randomised clinical trial: delayed‐release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing – ASCEND I and II combined analysis , 2011, Alimentary pharmacology & therapeutics.

[61]  M. Schwab,et al.  ABCB1 Single‐Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis , 2011, Clinical pharmacology and therapeutics.

[62]  E. Horváth-Puhó,et al.  Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study , 2011, Gut.

[63]  J. Church,et al.  Influence of age at ileoanal pouch creation on long‐term changes in functional outcomes , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[64]  A. Vcev,et al.  Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[65]  M. Zeitz,et al.  Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy , 2011, Inflammatory bowel diseases.

[66]  E. Weiss,et al.  Ileal pouch–anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[67]  D. Present,et al.  Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis , 2011, Journal of clinical gastroenterology.

[68]  L. A. Christensen,et al.  Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. , 2011, Journal of Crohn's & colitis.

[69]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[70]  I. Lawrance.  Topical agents for idiopathic distal colitis and proctitis , 2011, Journal of gastroenterology and hepatology.

[71]  S. Targan,et al.  Randomised clinical trial: herbal extract HMPL‐004 in active ulcerative colitis – a double‐blind comparison with sustained release mesalazine , 2011, Alimentary pharmacology & therapeutics.

[72]  C. Taxonera,et al.  Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab , 2010, Alimentary pharmacology & therapeutics.

[73]  A. Ford,et al.  Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[74]  L. Mackillop,et al.  European evidenced-based consensus on reproduction in inflammatory bowel disease. , 2010, Journal of Crohn's & colitis.

[75]  Z. Cohen,et al.  Oncologic Outcome in Patients With Ulcerative Colitis Associated With Dyplasia or Cancer Who Underwent Stapled or Handsewn Ileal Pouch-Anal Anastomosis , 2010, Diseases of the colon and rectum.

[76]  M. Vieth,et al.  Clinical trial: A novel high‐dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500‐mg suppository thrice daily in active ulcerative proctitis , 2010, Inflammatory bowel diseases.

[77]  S. Targan,et al.  Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis , 2010, Gut.

[78]  W. Reinisch,et al.  Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. , 2010, Journal of Crohn's & colitis.

[79]  P. Hellström,et al.  Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study , 2010, Alimentary pharmacology & therapeutics.

[80]  Fraser Cummings,et al.  The pattern and outcome of acute severe colitis. , 2010, Journal of Crohn's & colitis.

[81]  J. Fleshman,et al.  Laparoscopic versus open 2-stage ileal pouch: laparoscopic approach allows for faster restoration of intestinal continuity. , 2010, Journal of the American College of Surgeons.

[82]  M. Cheang,et al.  A Prospective Population-Based Study of Triggers of Symptomatic Flares in IBD , 2010, The American Journal of Gastroenterology.

[83]  P. Marteau,et al.  Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine , 2010, European journal of gastroenterology & hepatology.

[84]  S. Brand,et al.  Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis , 2010, The American Journal of Gastroenterology.

[85]  N. Gupta,et al.  Postoperative Outcome of Colectomy for Pediatric Patients With Ulcerative Colitis , 2010, Journal of pediatric gastroenterology and nutrition.

[86]  H. Tajiri,et al.  What's Hot in the Red Journal This Month? , 2010, The American Journal of Gastroenterology.

[87]  R. Fedorak,et al.  Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort , 2010, Alimentary pharmacology & therapeutics.

[88]  M. Lamet.  A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis , 2010, Digestive Diseases and Sciences.

[89]  C. Brunet,et al.  Very Low Stapling of the Anal Canal in Laparoscopic Ileal Pouch-Anal Anastomosis , 2010, Diseases of the colon and rectum.

[90]  F. Carrat,et al.  Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy , 2010, Gut.

[91]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[92]  K. Fellermann,et al.  Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus , 2010, Alimentary pharmacology & therapeutics.

[93]  T. Chiba,et al.  Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus , 2010, Journal of gastroenterology and hepatology.

[94]  M. Jiang,et al.  Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. , 2010, World journal of gastroenterology.

[95]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[96]  P. Gaburri,et al.  Azathioprine maintains long‐term steroid‐free remission through 3 years in patients with steroid‐dependent ulcerative colitis† , 2010, Inflammatory bowel diseases.

[97]  J. Korzenik,et al.  Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. , 2010, Gastroenterology.

[98]  J. Dillon,et al.  OC-031 Outreach community testing for hepatitis C in an ethnic population , 2010, Gut.

[99]  S. Vavricka,et al.  Clinical trial: five or ten cycles of granulocyte–monocyte apheresis show equivalent efficacy and safety in ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[100]  B. Flourié,et al.  Infliximab for refractory ulcerative proctitis , 2010, Alimentary pharmacology & therapeutics.

[101]  B. Warren,et al.  Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications , 2010, The British journal of surgery.

[102]  O. Inatomi,et al.  Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis , 2010, Journal of gastroenterology and hepatology.

[103]  L. Guidi,et al.  P.96 EFFECT OF ANTI-TNF-ALPHA TREATMENT ON SHORT-TERM POST-OPERATIVE COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE , 2010 .

[104]  R. Hodin,et al.  Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery , 2010, International Journal of Colorectal Disease.

[105]  J. West,et al.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study , 2010, The Lancet.

[106]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[107]  P. Gentile,et al.  Mesalazine vanishing time from rectal mucosa following its topical administration. , 2010, Journal of Crohn's & colitis.

[108]  Zhiping Yang,et al.  Meta‐analysis: pre‐operative infliximab treatment and short‐term post‐operative complications in patients with ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[109]  L. Peyrin-Biroulet,et al.  Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. , 2010, Current drug targets.

[110]  M. Barthet,et al.  Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch–anal anastomosis: a case-matched study , 2010, Surgical Endoscopy.

[111]  M. Thabane,et al.  Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[112]  T. Hibi,et al.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study , 2010, Inflammatory bowel diseases.

[113]  I. Lavery,et al.  Clinical outcomes of ileorectal anastomosis for ulcerative colitis , 2009, The British journal of surgery.

[114]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[115]  M. Campieri,et al.  Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol® , 2009, Alimentary pharmacology & therapeutics.

[116]  S. Riordan,et al.  Appendicectomy as a Therapy for Ulcerative Proctitis , 2009, The American Journal of Gastroenterology.

[117]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[118]  V. Fazio,et al.  Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. , 2009, Surgery.

[119]  D. Rubin,et al.  Open‐label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab , 2009, Inflammatory bowel diseases.

[120]  J. Maul,et al.  Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[121]  S. McCartney,et al.  Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine , 2009, Alimentary pharmacology & therapeutics.

[122]  G. Kolios,et al.  Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? , 2009, European Journal of Clinical Pharmacology.

[123]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[124]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[125]  V. Fazio,et al.  Outcomes for Patients Undergoing Continent Ileostomy After a Failed Ileal Pouch-Anal Anastomosis , 2009, Diseases of the colon and rectum.

[126]  P. Ciclitira,et al.  Guide to endoscopy of the ileo‐anal pouch following restorative proctocolectomy with ileal pouch‐anal anastomosis; indications, technique, and management of common findings , 2009, Inflammatory bowel diseases.

[127]  G. Porro,et al.  Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal , 2009, The American Journal of Gastroenterology.

[128]  P. Rutgeerts,et al.  Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis , 2009, Inflammatory bowel diseases.

[129]  J. Mate,et al.  Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis , 2009, Alimentary pharmacology & therapeutics.

[130]  T. Stijnen,et al.  Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[131]  S. Nikfar,et al.  A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis , 2009, Digestive Diseases and Sciences.

[132]  H. Masnou,et al.  Infliximab Rescue Therapy after Cyclosporin Failure in Steroid-Refractory Ulcerative Colitis , 2009, Digestion.

[133]  O. Dewit,et al.  561 Successive Treatment with Cyclosporine and Infliximab in Severe Ulcerative Colitis (UC) , 2009 .

[134]  S. Nikfar,et al.  Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis , 2009, Digestive Diseases and Sciences.

[135]  D. Larson,et al.  Minimally Invasive Subtotal Colectomy and Ileal Pouch-Anal Anastomosis for Fulminant Ulcerative Colitis: A Reasonable Approach? , 2009, Diseases of the colon and rectum.

[136]  E. Kuipers,et al.  Local application of tacrolimus in distal colitis: Feasible and safe , 2009, Inflammatory bowel diseases.

[137]  R. Baldassano,et al.  Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[138]  W. Bemelman,et al.  Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. , 2009, The Cochrane database of systematic reviews.

[139]  M. Vatn,et al.  Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) , 2009, Scandinavian journal of gastroenterology.

[140]  M. Kamm,et al.  Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis , 2009, Inflammatory bowel diseases.

[141]  P. Munkholm,et al.  Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[142]  I. Lawrance,et al.  Rectal tacrolimus in the treatment of resistant ulcerative proctitis , 2008, Alimentary pharmacology & therapeutics.

[143]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[144]  L. Peyrin-Biroulet,et al.  Long‐term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single‐centre experience , 2008, Alimentary pharmacology & therapeutics.

[145]  R. Vega,et al.  Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy , 2008, Inflammatory bowel diseases.

[146]  A. Kornbluth,et al.  Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[147]  R. Franchis,et al.  Oral, colonic‐release low‐molecular‐weight heparin: an initial open study of Parnaparin‐MMX for the treatment of mild‐to‐moderate left‐sided ulcerative colitis , 2008, Alimentary pharmacology & therapeutics.

[148]  S. Saxena,et al.  Preoperative Steroid Use and Risk of Postoperative Complications in Patients With Inflammatory Bowel Disease Undergoing Abdominal Surgery , 2008, The American Journal of Gastroenterology.

[149]  T. Chiba,et al.  Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis , 2008, Alimentary pharmacology & therapeutics.

[150]  J. Henker,et al.  Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. , 2008, Zeitschrift fur Gastroenterologie.

[151]  K. Van Steen,et al.  Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[152]  J. Korzenik,et al.  Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications , 2008, Journal of Gastrointestinal Surgery.

[153]  T. Hibi,et al.  Randomized , Double-Blind , Sham-Controlled Study of ranulocyte / Monocyte Apheresis for Active Ulcerative Colitis , 2008 .

[154]  J. Lefèvre,et al.  Laparoscopic 3-step Restorative Proctocolectomy: Comparative Study With Open Approach in 45 Patients , 2008, Surgical laparoscopy, endoscopy & percutaneous techniques.

[155]  B. Feagan,et al.  Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. , 2008, The Cochrane database of systematic reviews.

[156]  F. Remzi,et al.  Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy , 2008, Diseases of the colon and rectum.

[157]  P. Tekkis,et al.  Assessment of the mucosa of the indefinitely diverted ileo‐anal pouch , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[158]  G. Kaplan,et al.  A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.

[159]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[160]  M. Kamm,et al.  MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations , 2008, Alimentary pharmacology & therapeutics.

[161]  Dawn B. Beaulieu,et al.  History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis , 2008, Inflammatory bowel diseases.

[162]  R. Lovegrove,et al.  Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. , 2008, Archives of surgery.

[163]  P. Lakatos,et al.  Ulcerative proctitis: a review of pharmacotherapy and management , 2008, Expert opinion on pharmacotherapy.

[164]  W. Cacheux,et al.  Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis , 2008, The American Journal of Gastroenterology.

[165]  S. Schreiber,et al.  Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.

[166]  A. Buchman,et al.  Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: A single‐center experience , 2008, Inflammatory bowel diseases.

[167]  A. Lavy,et al.  Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[168]  Z. Cohen,et al.  Improved Outcome Due to Increased Experience and Individualized Management of Leaks After Ileal Pouch-Anal Anastomosis , 2007, Annals of surgery.

[169]  S. Radley,et al.  Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis , 2007, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[170]  M. Goldacre,et al.  Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies , 2007, BMJ : British Medical Journal.

[171]  D. McKay,et al.  Probiotics for induction of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[172]  P. Tekkis,et al.  Quality of life after indefinite diversion/pouch excision in ileal pouch failure patients , 2007, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[173]  S. Kuriyama,et al.  Effect of weekend 5‐aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a randomized controlled study , 2007, Inflammatory bowel diseases.

[174]  A. Gasbarrini,et al.  Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up , 2007, Alimentary pharmacology & therapeutics.

[175]  S. Targan,et al.  Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis? , 2007, Diseases of the colon and rectum.

[176]  C. Lees,et al.  A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[177]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[178]  K. Whelan,et al.  Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials , 2007, Proceedings of the Nutrition Society.

[179]  M. Kamm,et al.  MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials , 2007, Alimentary pharmacology & therapeutics.

[180]  F. Manguso,et al.  Meta‐analysis: the efficacy of rectal beclomethasone dipropionate vs. 5‐aminosalicylic acid in mild to moderate distal ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[181]  P. Rutgeerts,et al.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.

[182]  A. Darzi,et al.  The Effect of Restorative Proctocolectomy on Sexual Function, Urinary Function, Fertility, Pregnancy and Delivery: A Systematic Review , 2007, Diseases of the colon and rectum.

[183]  Y. Panis,et al.  Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. , 2007, Surgery.

[184]  S. Travis,et al.  Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006 , 2007, Alimentary pharmacology & therapeutics.

[185]  D. Hommes,et al.  Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis , 2007, The British journal of surgery.

[186]  W. Harmsen,et al.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. , 2007, Journal of the American College of Surgeons.

[187]  L. Peyrin-Biroulet,et al.  Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. , 2007, World journal of gastroenterology.

[188]  P. Munkholm,et al.  Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population‐Based Study from Copenhagen, Denmark , 2007, Inflammatory bowel diseases.

[189]  A. Sapino,et al.  Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study , 2007, BMC gastroenterology.

[190]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[191]  Konstantinos H. Katsanos,et al.  Predictors of early response to infliximab in patients with ulcerative colitis , 2007, Inflammatory bowel diseases.

[192]  C. Brensinger,et al.  A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. , 2007, Gastroenterology.

[193]  O. Zmora,et al.  Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives? , 2007, International Journal of Colorectal Disease.

[194]  S. O'dwyer,et al.  The fate of the rectal stump after subtotal colectomy for ulcerative colitis , 2007, International Journal of Colorectal Disease.

[195]  P. Hillerås,et al.  Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis , 2007, Scandinavian journal of gastroenterology.

[196]  Sanyuan Hu,et al.  Laparoscopic versus open proctocolectomy with ileal pouch‐anal anastomosis , 2007, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[197]  M. Sata,et al.  Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[198]  A. H. Zwinderman,et al.  Effect of vaginal delivery on long‐term pouch function , 2006, The British journal of surgery.

[199]  A. Moss,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.

[200]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[201]  S. Hanauer,et al.  Review article: high‐dose aminosalicylates to induce and maintain remissions in ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[202]  H. Steinhart,et al.  Medical management of left‐sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials , 2006, Inflammatory bowel diseases.

[203]  L. Hultén,et al.  The place for colectomy and ileorectal anastomosis: a valid surgical option for ulcerative colitis? , 2006, Techniques in Coloproctology.

[204]  A. Akobeng,et al.  Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. , 2006, The Cochrane database of systematic reviews.

[205]  R. Pollok,et al.  Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators , 2006, The British journal of surgery.

[206]  A. Darzi,et al.  A Comparison of Hand-Sewn Versus Stapled Ileal Pouch Anal Anastomosis (IPAA) Following Proctocolectomy: A Meta-Analysis of 4183 Patients , 2006, Annals of surgery.

[207]  M. Regueiro,et al.  Infliximab for Hospitalized Patients With Severe Ulcerative Colitis , 2006, Journal of clinical gastroenterology.

[208]  R. Burakoff,et al.  Use of antibiotics in the treatment of inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[209]  P. Rutgeerts,et al.  Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[210]  A. Gasbarrini,et al.  Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[211]  N. Shepherd,et al.  Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease , 2006, Alimentary pharmacology & therapeutics.

[212]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[213]  B. Wiedenmann,et al.  Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease—A Long-Term Follow-Up , 2006, The American Journal of Gastroenterology.

[214]  S. Targan,et al.  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial , 2006, Gut.

[215]  M. Portella,et al.  Life Events and Inflammatory Bowel Disease Relapse: A Prospective Study of Patients Enrolled in Remission , 2006, The American Journal of Gastroenterology.

[216]  G. Radford-Smith,et al.  Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[217]  J. Colombel,et al.  Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. , 2006, Gastroenterologie clinique et biologique.

[218]  G. Holtmann,et al.  [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine]. , 2006, Zeitschrift fur Gastroenterologie.

[219]  T. Matsui,et al.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.

[220]  A. Forbes,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.

[221]  J. Connor,et al.  Long-Term Outcome and Quality of Life After Continent Ileostomy , 2006, Diseases of the colon and rectum.

[222]  D. Rampton,et al.  Review article: complementary and alternative therapies for inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[223]  Simon Smale,et al.  Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[224]  W. Sandborn,et al.  Preliminary data on the use of apheresis in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[225]  R. Playford,et al.  Combined PET/CT colonography: is this the way forward? , 2005, Gut.

[226]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[227]  S. Travis.  What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis? , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[228]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[229]  T. Young‐Fadok,et al.  Laparoscopic-Assisted vs. Open Ileal Pouch-Anal Anastomosis: Functional Outcome in a Case-Matched Series , 2005, Diseases of the colon and rectum.

[230]  E. Torres,et al.  Surveillance for Dysplasia in Patients with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: An Interim Analysis , 2005, Digestive Diseases and Sciences.

[231]  I. Ekman,et al.  Thirty Years of Experience Living With a Continent Ileostomy , 2005, Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society.

[232]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[233]  J. Church,et al.  Vaginal Delivery After Ileal Pouch-Anal Anastomosis: A Word of Caution , 2005, Diseases of the colon and rectum.

[234]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[235]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[236]  P. Marteau,et al.  An unusual cause of soft tissue infection , 2005, Gut.

[237]  D. Larson,et al.  Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? , 2005, Archives of surgery.

[238]  A. Munakata,et al.  Leukocytapheresis in Ulcerative Colitis: Results of a Multicenter Double-Blind Prospective Case-Control Study with Sham Apheresis as Placebo Treatment , 2005, The American Journal of Gastroenterology.

[239]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[240]  O. Paoluzi,et al.  Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study , 2005, Alimentary pharmacology & therapeutics.

[241]  A. Forbes,et al.  Multicentre randomized‐controlled clinical trial of Ipocol, a new enteric‐coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis , 2005, Alimentary pharmacology & therapeutics.

[242]  Joel V Weinstock,et al.  Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. , 2005, Gastroenterology.

[243]  D. Margolin,et al.  Continent Ileostomy: Current Experience , 2005, Diseases of the colon and rectum.

[244]  H. Järvinen,et al.  Fate of the Rectum after Colectomy with Ileorectal Anastomosis in Ulcerative Colitis , 2005, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[245]  G. Corrao,et al.  Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[246]  H. Drummond,et al.  Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. , 2005, Gastroenterology.

[247]  Feza H. Remzi,et al.  Evaluation of the Learning Curve in Ileal Pouch–Anal Anastomosis Surgery , 2005, Annals of surgery.

[248]  S. Lledó,et al.  A Prospective Audit of the Complications of Loop Ileostomy Construction and Takedown , 2005, Digestive Surgery.

[249]  K. Soares-Weiser,et al.  Cyclosporine A for induction of remission in severe ulcerative colitis. , 2005, The Cochrane database of systematic reviews.

[250]  N. Hyman,et al.  Urgent Subtotal Colectomy for Severe Inflammatory Bowel Disease , 2005, Diseases of the colon and rectum.

[251]  D. Jewell,et al.  Ciclosporin use in acute ulcerative colitis: a long-term experience , 2005, European journal of gastroenterology & hepatology.

[252]  U. Ghoshal,et al.  Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. , 2004, Journal of medical microbiology.

[253]  R. Willén,et al.  The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: A long‐term term follow‐up study , 2004, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[254]  T. Yamamoto,et al.  Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study , 2004, Alimentary pharmacology & therapeutics.

[255]  V. Fazio,et al.  Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. , 2004, Surgery.

[256]  L. Hultén,et al.  The failed pelvic pouch: conversion to a continent ileostomy , 2004, Techniques in Coloproctology.

[257]  R. Beart,et al.  Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch–anal anastomosis , 2004, Journal of Gastrointestinal Surgery.

[258]  V. Medici,et al.  Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[259]  B. Scott,et al.  How effective are the usual treatments for ulcerative colitis? , 2004, Alimentary pharmacology & therapeutics.

[260]  Hubert G M Leufkens,et al.  5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. , 2004, Gastroenterology.

[261]  R. Farouk,et al.  Pregnancy and Delivery Before and After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: Immediate and Long-Term Consequences and Outcomes , 2004, Diseases of the colon and rectum.

[262]  Z. Cohen,et al.  Female Infertility After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis , 2004, Diseases of the colon and rectum.

[263]  Yoshio Araki,et al.  Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. , 2004, International journal of molecular medicine.

[264]  W. Harmsen,et al.  Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy , 2004, American Journal of Gastroenterology.

[265]  R. Prescott,et al.  Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second‐line medical therapy or surgery , 2004, Alimentary pharmacology & therapeutics.

[266]  M. Karoui,et al.  Results of Surgical Removal of the Pouch After Failed Restorative Proctocolectomy , 2004, Diseases of the colon and rectum.

[267]  D. Jewell,et al.  Randomized, double‐blind, placebo‐controlled trial of oral aloe vera gel for active ulcerative colitis , 2004, Alimentary pharmacology & therapeutics.

[268]  O. Zmora,et al.  Outcome of Patients With Indeterminate Colitis Undergoing a Double-Stapled Ileal Pouch-Anal Anastomosis , 2004, Diseases of the colon and rectum.

[269]  P. Rutgeerts,et al.  Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis , 2004, Inflammatory bowel diseases.

[270]  N. Shafiq,et al.  Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond , 2004, Expert opinion on pharmacotherapy.

[271]  C. Delaney,et al.  Functional Outcome and Quality of Life After Repeat Ileal Pouch-Anal Anastomosis for Complications of Ileoanal Surgery , 2004, Diseases of the colon and rectum.

[272]  P. Guldberg,et al.  Screening for dysplasia and TP53 mutations in closed rectal stumps of patients with ulcerative colitis or Crohn disease , 2004, Scandinavian journal of gastroenterology.

[273]  D. Bjorkman,et al.  Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis , 2004 .

[274]  H. Tilg,et al.  A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis , 2003 .

[275]  P. Beck,et al.  A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management , 2003, American Journal of Gastroenterology.

[276]  T. Hibi,et al.  Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. , 2003, International journal of molecular medicine.

[277]  B. Nilsson,et al.  Obstetric sphincter tears and anal incontinence: an observational follow‐up study , 2003, Acta obstetricia et gynecologica Scandinavica.

[278]  Samir A. Shah,et al.  Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study , 2003, American Journal of Gastroenterology.

[279]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[280]  Y. Panis,et al.  Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. , 2003, Journal of the American College of Surgeons.

[281]  W. Petritsch,et al.  Effect of oral tacrolimus (FK 506) on steroid‐refractory moderate/severe ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[282]  H. Tulchinsky,et al.  Long-Term Failure After Restorative Proctocolectomy for Ulcerative Colitis , 2003, Annals of surgery.

[283]  J. Lewis,et al.  Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. , 2003, Gastroenterology.

[284]  R. Playford,et al.  Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. , 2003, The New England journal of medicine.

[285]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of extensive and left‐sided active ulcerative colitis: a multicentre randomised study , 2003, Alimentary pharmacology & therapeutics.

[286]  D. Huo,et al.  A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[287]  A. Forbes,et al.  Review article: oral, modified‐release mesalazine formulations — proprietary versus generic , 2003, Alimentary pharmacology & therapeutics.

[288]  B. Wiedenmann,et al.  Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[289]  A. Sood,et al.  Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. , 2003, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[290]  T. Öresland,et al.  Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis – a prospective study , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[291]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[292]  S. Laurberg,et al.  Female fecundity before and after operation for familial adenomatous polyposis , 2003, The British journal of surgery.

[293]  H. Ishikawa,et al.  Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis , 2003, Journal of the American College of Nutrition.

[294]  T. Hibi,et al.  Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. , 2003, Current pharmaceutical design.

[295]  G. Makin,et al.  Mortality, morbidity and functional outcome after ileorectal anastomosis , 2003, The British journal of surgery.

[296]  E. Cabré,et al.  Azathioprine without oral ciclosporin in the long‐term maintenance of remission induced by intravenous ciclosporin in severe, steroid‐refractory ulcerative colitis , 2002, Alimentary pharmacology & therapeutics.

[297]  K. Fellermann,et al.  Response of Refractory Colitis to Intravenous or Oral Tacrolimus (FK506) , 2002, Inflammatory bowel diseases.

[298]  A. Zinsmeister,et al.  Azathioprine or 6-Mercaptopurine Before Colectomy for Ulcerative Colitis Is Not Associated With Increased Postoperative Complications , 2002, Inflammatory bowel diseases.

[299]  E. Tiret,et al.  [Ileal pouch anal-anastomosis without protective ileostomy]. , 2002, Gastroenterologie clinique et biologique.

[300]  A. Andoh,et al.  A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis , 2002, Journal of gastroenterology and hepatology.

[301]  C. Delaney,et al.  Equivalent Function, Quality of Life and Pouch Survival Rates After Ileal Pouch-Anal Anastomosis for Indeterminate and Ulcerative Colitis , 2002, Annals of surgery.

[302]  J. Church,et al.  Functional Outcome, Quality of Life, and Complications After Ileal Pouch-Anal Anastomosis in Selected Septuagenarians , 2002, Diseases of the colon and rectum.

[303]  D. F. Berg,et al.  Acute surgical emergencies in inflammatory bowel disease. , 2002, American journal of surgery.

[304]  D. Levine,et al.  A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[305]  P. Testoni,et al.  Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[306]  A. Sood,et al.  The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis , 2002, Journal of Gastroenterology.

[307]  R. Willén,et al.  Mucosal Assessment for Dysplasia and Cancer in the Ileal Pouch Mucosa in Patients Operated on for Ulcerative Colitis—A 30-Year Follow-Up Study , 2002, Diseases of the colon and rectum.

[308]  D. Jewell,et al.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review , 2002, Gut.

[309]  D. Jewell,et al.  The efficacy of methotrexate for maintaining remission in inflammatory bowel disease , 2002, Alimentary pharmacology & therapeutics.

[310]  M. Stolte,et al.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.

[311]  C. Herfarth,et al.  One- or Two-stage Procedure for Restorative Proctocolectomy: Rationale for a Surgical Strategy in Ulcerative Colitis , 2001, Annals of surgery.

[312]  D. Jewell,et al.  Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications , 2001, Diseases of the colon and rectum.

[313]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[314]  K. Petraki,et al.  A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 2001, Scandinavian journal of gastroenterology.

[315]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[316]  S. Targan,et al.  Outcome of cytomegalovirus infections in patients with inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[317]  D. Richards,et al.  Patient quality of life after successful restorative proctocolectomy is normal , 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[318]  M. Pocard,et al.  Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease , 2001, Diseases of the colon and rectum.

[319]  S. Targan,et al.  Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.

[320]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[321]  Y. Kohgo,et al.  Effect of Ecabet Sodium Enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study , 2001, American Journal of Gastroenterology.

[322]  J. Church.  Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. , 2000, The Australian and New Zealand journal of surgery.

[323]  R. Moreno-otero,et al.  6‐Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[324]  Z H Khan,et al.  Retrospective Case Series Analysis of Patients with Inflammatory Bowel Disease on Azathioprine , 2000, Digestion.

[325]  L. Good,et al.  Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis , 2000, American Journal of Gastroenterology.

[326]  S. Levenstein,et al.  Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission , 2000, American Journal of Gastroenterology.

[327]  J. Church,et al.  Laparoscopic restorative proctocolectomy , 2000, Diseases of the colon and rectum.

[328]  A. Cross,et al.  Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis , 2000 .

[329]  Carbonnel,et al.  Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis , 2000, Alimentary pharmacology & therapeutics.

[330]  Hebden,et al.  Limited exposure of the healthy distal colon to orally‐dosed formulation is further exaggerated in active left‐sided ulcerative colitis , 2000, Alimentary Pharmacology and Therapeutics.

[331]  P. Balladur,et al.  Restorative proctocolectomy for distal ulcerative colitis , 1999, Gut.

[332]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[333]  F. Casellas,et al.  Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis. , 1999, Hepato-gastroenterology.

[334]  H. Yan,et al.  Observation of the efficacy of acupuncture and moxibustion in 62 cases of chronic colitis. , 1999, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[335]  S. Hanauer,et al.  Intravenous cyclosporin in ulcerative colitis: a five-year experience , 1999, American Journal of Gastroenterology.

[336]  N. Kneteman,et al.  Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). , 1999, Transplantation.

[337]  S. Laurberg,et al.  Fertility after ileal pouch–anal anastomosis in women with ulcerative colitis , 1999, The British journal of surgery.

[338]  Ardizzone,et al.  Is maintenance therapy always necessary for patients with ulcerative colitis in remission? , 1999, Alimentary pharmacology & therapeutics.

[339]  M. Färkkilä,et al.  Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. , 1998, Gastroenterology.

[340]  D. Present,et al.  Ciprofloxacin as a treatment for ulcerative colitis-not yet. , 1998, Gastroenterology.

[341]  R. Löfberg,et al.  Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis , 1998, European journal of gastroenterology & hepatology.

[342]  X. Zhang.  23 cases of chronic nonspecific ulcerative colitis treated by acupuncture and moxibustion. , 1998, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[343]  G. Porro,et al.  Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial , 1998, American Journal of Gastroenterology.

[344]  V. Litle,et al.  The continent ileostomy: Long-term durability and patient satisfaction , 1998, Journal of Gastrointestinal Surgery.

[345]  F. Saibil.  Lidocaine enemas for intractable distal ulcerative colitis (IDUC): Efficacy and safety , 1998 .

[346]  P. Marteau,et al.  Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study , 1998, Gut.

[347]  P. Gionchetti,et al.  Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.

[348]  J. Chen,et al.  Clinical therapeutic effect of drug-separated moxibustion on chronic diarrhea and its immunologic mechanisms. , 1997, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[349]  M. Stolte,et al.  Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis , 1997, Alimentary pharmacology & therapeutics.

[350]  S. Targan,et al.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.

[351]  J. Mayberry,et al.  Oral or rectal administration of drugs in IBD? , 1997, Alimentary pharmacology & therapeutics.

[352]  G. Porro,et al.  Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. , 1997, Journal of clinical gastroenterology.

[353]  A. Amorosi,et al.  Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. , 1997, The American journal of gastroenterology.

[354]  J. Satsangi,et al.  Genetic markers may predict disease behavior in patients with ulcerative colitis. , 1997, Gastroenterology.

[355]  J. Marshall,et al.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.

[356]  A. Rademaker,et al.  Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. , 1997, Gut.

[357]  L. Dubé,et al.  A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. , 1997, Gastroenterology.

[358]  É. Lerebours,et al.  Intravenous cyclosporine in attacks of ulcerative colitis , 1996, Digestive Diseases and Sciences.

[359]  E. Cabré,et al.  Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. , 1996, The American journal of gastroenterology.

[360]  German and Austrian ImipenemCilastatin Study Group,et al.  Treatment of distal ulcerative colitis with short-chain fatty acid enemas a placebo-controlled trial , 1996, Digestive Diseases and Sciences.

[361]  G. Feifel,et al.  Conversion of the failing ileoanal pouch to reservoir-ileostomy rather than to ileostomy alone , 1996, Diseases of the colon and rectum.

[362]  C. Bodian,et al.  The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. , 1996, The American journal of gastroenterology.

[363]  P. Nyström,et al.  Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis , 1996, The Lancet.

[364]  A. V. van Bodegraven,et al.  Distribution of mesalazine enemas in active and quiescent ulcerative colitis. , 1996, Alimentary pharmacology & therapeutics.

[365]  P. Fockens,et al.  Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. , 1996, European journal of gastroenterology & hepatology.

[366]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[367]  A. Lavy,et al.  Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. , 1996, Gastroenterology.

[368]  R. Motson,et al.  Incidence of third‐degree perineal tears in labour and outcome after primary repair , 1996, The British journal of surgery.

[369]  S. Hanauer,et al.  An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.

[370]  G. Porro,et al.  Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. , 1995, Journal of clinical gastroenterology.

[371]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis , 1995 .

[372]  J. Marshall,et al.  Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis , 1995, Alimentary pharmacology & therapeutics.

[373]  M. Stolte,et al.  Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. , 1995, European journal of gastroenterology & hepatology.

[374]  S. Hanauer,et al.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis , 1995, Digestive Diseases and Sciences.

[375]  Anne Lavergne,et al.  Colonoscopy of acute colitis , 1994, Digestive Diseases and Sciences.

[376]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[377]  K. Batts,et al.  A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. , 1994, Gastroenterology.

[378]  N. Crona,et al.  Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy , 1994, International Journal of Colorectal Disease.

[379]  L. Hultén,et al.  Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? , 1994, Diseases of the colon and rectum.

[380]  K. Petraki,et al.  Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis , 1994, Diseases of the colon and rectum.

[381]  M. Panos,et al.  Toxic megacolon: the knee-elbow position relieves bowel distension. , 1993, Gut.

[382]  E. Cabré,et al.  Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. , 1993, The American journal of gastroenterology.

[383]  A. Axon,et al.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.

[384]  K. Ladefoged,et al.  Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. , 1992, Gut.

[385]  D. Jewell,et al.  Small bowel gas in severe ulcerative colitis. , 1991, Gut.

[386]  Z. Cohen,et al.  Subtotal colectomy for ulcerative colitis: Complications related to the rectal remnant , 1991, Diseases of the colon and rectum.

[387]  R. Beart,et al.  Ileal pouch-anal anastomosis without ileostomy , 1991, Diseases of the colon and rectum.

[388]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[389]  M. Swash,et al.  Effect of vaginal delivery on the pelvic floor: A 5‐year follow‐up , 1990, The British journal of surgery.

[390]  F. D'armiento,et al.  5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. , 1990, The American journal of gastroenterology.

[391]  J. Paulley,et al.  Reply , 1990, Gut.

[392]  Adler Dj,et al.  The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. , 1990 .

[393]  A. Axon,et al.  The role of azathioprine in the management of ulcerative colitis , 1990, Diseases of the colon and rectum.

[394]  M. Milla,et al.  Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis , 1990, Diseases of the colon and rectum.

[395]  D. Johnston,et al.  The efficacy of tobramycin in the treatment of ulcerative colitis , 1990, Alimentary pharmacology & therapeutics.

[396]  R. Löfberg,et al.  Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County , 1990, Diseases of the colon and rectum.

[397]  S. Riley,et al.  Why do patients with ulcerative colitis relapse? , 1990, Gut.

[398]  S. Huang,et al.  Treatment of mucous membrane diseases of the digestive tract with jing jie lian qiao tang--therapeutic effect in 168 cases. , 1989, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[399]  A. Forbes,et al.  Safety and efficacy of acetarsol suppositories in unresponsive proctitis , 1989, Alimentary pharmacology & therapeutics.

[400]  Z. Fireman,et al.  A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. , 1989, Journal of clinical gastroenterology.

[401]  H. Goebell,et al.  [The course and prognosis of ulcerative colitis]. , 1989, Medizinische Klinik.

[402]  R. Kozarek,et al.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.

[403]  H. Janowitz,et al.  The "natural history" of ulcerative colitis: an analysis of the placebo response. , 1989, Journal of clinical gastroenterology.

[404]  P. Blok,et al.  Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. , 1988, Gastroenterology.

[405]  D. Jewell,et al.  High‐Dose Methylprednisolone in the Treatment of Active Ulcerative Colitis , 1988, Journal of clinical gastroenterology.

[406]  J. G. Walker,et al.  Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine , 1988, Alimentary pharmacology & therapeutics.

[407]  S. Riley,et al.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.

[408]  D. Jewell,et al.  Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. , 1986, Gut.

[409]  J. Lennard-jones,et al.  Controlled trial of bowel rest in the treatment of severe acute colitis. , 1986, Gut.

[410]  W. Kraaz,et al.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. , 1986, Gastroenterology.

[411]  A. Axon,et al.  Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. , 1985, Gut.

[412]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[413]  M. Swash,et al.  INJURY TO INNERVATION OF PELVIC FLOOR SPHINCTER MUSCULATURE IN CHILDBIRTH , 1984, The Lancet.

[414]  R. Beart,et al.  Fate of the rectal mucosa after rectal mucosectomy and ileoanal anastomosis , 1983, Diseases of the colon and rectum.

[415]  I. Lavery,et al.  Cancer in the excluded rectum following surgery for inflammatory bowel disease , 1982, Diseases of the colon and rectum.

[416]  S. Truelove,et al.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. , 1980, Gut.

[417]  J. Dyerberg,et al.  TRANEXAMIC ACID: A NEW APPROACH TO AUTOIMMUNE DISEASE ? , 1975, The Lancet.

[418]  C. Spicer,et al.  Assessment of severity in colitis: a preliminary study. , 1975, Gut.

[419]  D. Jewell,et al.  Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial , 1974, British medical journal.

[420]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[421]  S. Truelove,et al.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) , 1973, Gut.

[422]  R. Wright,et al.  Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets , 1966, The American Journal of Digestive Diseases.

[423]  R. May,et al.  Sexual dysfunction following rectal excision for ulcerative colitis , 1966, The British journal of surgery.

[424]  J. H. Baron,et al.  CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS , 1965 .

[425]  S. Truelove,et al.  Comparison of Corticosteroid and Sulphasalazine Therapy in Ulcerative Colitis , 1962, British medical journal.

[426]  J. H. Baron,et al.  Out-patient Treatment of Ulcerative Colitis , 1962, British medical journal.

[427]  F. Jones,et al.  An Assessment of Prednisone, Salazopyrin, and Topical Hydrocortisone Hemisuccinate Used as Out-patient Treatment for Ulcerative Colitis , 1960, Gut.

[428]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[429]  L. Witts,et al.  Cortisone in Ulcerative Colitis , 1954 .

[430]  S. Truelove.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. , 1954, Gastroenterologia.

[431]  S. Truelove,et al.  ULCERATIVE COLITIS COURSE AND PROGNOSIS , 1950 .

[432]  T. L. Hardy,et al.  ULCERATIVE COLITIS , 1933, British medical journal.

[433]  L. Peyrin-Biroulet,et al.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[434]  M. Skup,et al.  Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. , 2014, Gastroenterology.

[435]  C. Kelly,et al.  Clostridium difficile infection in the inflammatory bowel disease patient. , 2013, Inflammatory bowel diseases.

[436]  R. Lovegrove,et al.  To divert or not to divert: A retrospective analysis of variables that influence ileostomy omission in ileal pouch surgery. , 2011, Archives of surgery.

[437]  D. Beddy,et al.  Volume analysis of outcome following restorative proctocolectomy , 2011 .

[438]  M. Picco.  Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis , 2011 .

[439]  M. Picco.  Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers , 2011 .

[440]  A. Ananthakrishnan,et al.  Clostridium difficile and inflammatory bowel disease. , 2010, The Medical clinics of North America.

[441]  A. Griffiths,et al.  Oral budesonide for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[442]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[443]  M. Picco.  Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis , 2009 .

[444]  J. Lefèvre,et al.  Total laparoscopic ileal pouch-anal anastomosis: prospective series of 82 patients , 2008, Surgical Endoscopy.

[445]  G. Lichtenstein.  Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial , 2008 .

[446]  J. Barkin.  Impact of Clostridium difficile on Inflammatory Bowel Disease , 2008 .

[447]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[448]  A. Griffiths,et al.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[449]  A. Bousvaros,et al.  Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. , 2007, Journal of pediatric surgery.

[450]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[451]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[452]  A. Griffiths,et al.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[453]  K. Bland.  Hand-Assisted Laparoscopic Versus Open Restorative Proctocolectomy With Ileal Pouch Anal Anastomosis: A Randomized Trial , 2006 .

[454]  S. Travis,et al.  Management of acute severe colitis. , 2005, British medical bulletin.

[455]  Irccs Ospedale.  Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis , 2005 .

[456]  R. McKee,et al.  Colectomy for acute colitis: is it safe to close the rectal stump? , 2004, International Journal of Colorectal Disease.

[457]  D. Bjorkman,et al.  Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. , 2004, Alimentary pharmacology & therapeutics.

[458]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.

[459]  D. Bjorkman,et al.  The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. , 2003, Reviews in gastroenterological disorders.

[460]  H. Tilg,et al.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. , 2003, Gut.

[461]  J. Macdonald,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2003, The Cochrane database of systematic reviews.

[462]  S. Laurberg,et al.  Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. , 2002, Gastroenterology.

[463]  A. Cohen,et al.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.

[464]  D. Bartolo,et al.  Selective omission of loop ileostomy in restorative proctocolectomy , 1998, International Journal of Colorectal Disease.

[465]  A. Lobo,et al.  Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. , 1998, Gastroenterology.

[466]  R. Lüdtke,et al.  Effects of Boswellia serrata gum resin in patients with ulcerative colitis. , 1997, European journal of medical research.

[467]  S. Hanauer,et al.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. , 1995, Digestive diseases and sciences.

[468]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. , 1995, European journal of gastroenterology & hepatology.

[469]  G. Mantzaris,et al.  Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 1994, The American journal of gastroenterology.

[470]  B. Korelitz,et al.  The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. , 1990, The American journal of gastroenterology.

[471]  M. Caruso,et al.  Ulcerative colitis in remission: it is possible to predict the risk of relapse? , 1989, Digestion.

[472]  C. H. Mason,et al.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Gut.

[473]  W. Johnson,et al.  The risk of rectal carcinoma following colectomy in ulcerative colitis , 1983, Diseases of the colon and rectum.

[474]  O. Bonnevie,et al.  The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. , 1973, Scandinavian journal of gastroenterology.

[475]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.